Development of dengue virus vaccine components

USRE46042E1 · kind E1 · reissue

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Stephen S. Whitehead · Montgomery Village, US
• Joseph E. Blaney · Frederick, US
• Brian R. Murphy · Bethesda, US
• Ching-Juh Lai · Bethesda, US

Key dates

• Filing date: May 16, 2013
• Grant date: Jun 28, 2016
• Expiry date: May 16, 2033

Classification

• Technology area (CPC —): General

Abstract

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.